FI3712131T3 - Neurotensiinireseptoriligandeja - Google Patents
Neurotensiinireseptoriligandeja Download PDFInfo
- Publication number
- FI3712131T3 FI3712131T3 FIEP20166422.4T FI20166422T FI3712131T3 FI 3712131 T3 FI3712131 T3 FI 3712131T3 FI 20166422 T FI20166422 T FI 20166422T FI 3712131 T3 FI3712131 T3 FI 3712131T3
- Authority
- FI
- Finland
- Prior art keywords
- compound according
- group
- acceptor
- effector
- disease
- Prior art date
Links
- 102000017922 Neurotensin receptor Human genes 0.000 title claims 2
- 108060003370 Neurotensin receptor Proteins 0.000 title claims 2
- 239000003446 ligand Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 28
- 239000012636 effector Substances 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 238000000034 method Methods 0.000 claims 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 239000002738 chelating agent Substances 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 125000001118 alkylidene group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 claims 2
- WQMQRNCPZFUGID-UHFFFAOYSA-N 2-azaniumyladamantane-2-carboxylate Chemical compound C1C(C2)CC3CC1C(C(O)=O)(N)C2C3 WQMQRNCPZFUGID-UHFFFAOYSA-N 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052738 indium Inorganic materials 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- KIUIVKNVSSLOAG-UHFFFAOYSA-N 1,4,7,10-tetrazacyclotridecan-11-one Chemical compound O=C1CCNCCNCCNCCN1 KIUIVKNVSSLOAG-UHFFFAOYSA-N 0.000 claims 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 1
- FHJXLSAWYORMMX-UHFFFAOYSA-N 9-aminobicyclo[3.3.1]nonane-9-carboxylic acid Chemical compound C1CCC2CCCC1C2(N)C(O)=O FHJXLSAWYORMMX-UHFFFAOYSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101000591385 Homo sapiens Neurotensin receptor type 1 Proteins 0.000 claims 1
- 229910052765 Lutetium Inorganic materials 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100033986 Neurotensin receptor type 1 Human genes 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 229910052733 gallium Inorganic materials 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (26)
1. Yhdiste, jolla on kaava (I): R! S W AA-COOH N O / OI N—ALK—NT RI Rt (1) 5 — jolloin R! on valittu ryhmästä, jonka muodostavat vety, metyyli ja syklopropyylimetyyli; AA-COOH on aminohappo valittuna ryhmästä, jonka muodostavat 2-amino-2-adaman- taanikarboksyylihappo, sykloheksyyliglysiini ja 9-aminobisyklo[3.3.1]nonaani-9-kar- boksyylihappo; R? on valittu ryhmästä, jonka muodostavat (C1-Ce)alkyyli, (C3-Cs)sykloalkyyli, (Cs- Cs)sykloalkyylimetyyli, halogeeni, nitro ja trifluorimetyyli; ALK on (C>-Cs)alkylideeni; R>, R' ja R* on kukin erikseen ja riippumattomasti valittu ryhmästä, jonka muodostavat vety ja (C1-Ca)alkyyli, edellyttäen, että yksi R>:sta, R*:std ja R3:std on seuraavan kaavan (II) mukainen 7 —ALKNT Re {Dn jolloin ALK’ on (C>-C5)alkylideeni; R* on valittu ryhmästä, jonka muodostavat vety ja (C1-Ca)alkyyli:; ja R? on efektoriosa, jolloin efektoriosa käsittää tai kykenee käsittämään efektorin, jolloin efektori on valittu ryhmästä, jonka muodostavat diagnostisesti aktiivinen nuklidi,
terapeuttisesti aktiivinen nuklidi ja niiden yhdistelmä; tai sen farmaseuttisesti hyväksyt- tävä suola, solvaatti tai hydraatti.
2. Patenttivaatimuksen 1 mukainen yhdiste, jossa efektoriosa on valittu ryhmästä, jonka muodostavat akseptori, -[akseptori-efektori], -[linkkeri-akseptori] ja -[linkkeri-ak- septori-efektori], jolloin akseptori on osa, joka välittää efektorin liittymistä kaavan (II) N-atomiin tai joka välittää efektorin liittymistä linkkeriin, efektori on valittu ryhmästä, joka käsittää diagnostisesti aktiivisen nuklidin ja te- — rapeuttisesti aktiivisen nuklidin, linkkeri on osa, joka liittää akseptorin kaavan (II) N-atomiin, -[akseptori-efektori] on osa, jossa efektori on kompleksoitunut tai kovalenttisesti sitoutunut akseptoriin, -[linkkeri-akseptori] on osa, jossa linkkeri on konjugoitunut akseptoriin, ja -[linkkeri-akseptori-efektori] on osa, jossa linkkeri on konjugoitunut akseptoriin, jolloin efektori on kompleksoitunut tai kovalenttisesti sitoutunut akseptoriin; jolloin link- kerin ja akseptorin välisen kovalenttisen sidoksen tyyppi on valittu ryhmästä, jonka muo- dostavat amidi, alkyyliamiini, urea, eetteri, tioeetteri, tiourea ja karbamaatti.
3. Jonkin patenttivaatimuksista 1 ja 2 mukainen yhdiste, jossa R! on metyyli.
4. Jonkin patenttivaatimuksista 1, 2 ja 3 mukainen yhdiste, jossa AA-COOH on aminohappo, joka on valittu ryhmästä, jonka muodostavat 2-amino-2-adamantaanikar- boksyylihappo ja sykloheksyyliglysiini.
5. Jonkin patenttivaatimuksista 1, 2, 3 ja 4, edullisesti jonkin patenttivaatimuksista 1 ja 2 mukainen yhdiste, jossa R? on isopropyyli.
6. Jonkin patenttivaatimuksista 1, 2, 3, 4 ja 5, edullisesti jonkin patenttivaatimuk- sista I ja 2 mukainen yhdiste, jossa R>, R* ja R on kukin erikseen ja riippumattomasti valittu ryhmästä, jonka muodostavat vety ja metyyli, edellyttäen, että yksi R?:sta, R*:stä ja R>:stä on seuraavan kaavan (II) mukainen
R —ALK—N R6 (IT) jolloin ALK’ on (C>-C5)alkylideeni; R* on valittu ryhmästä, jonka muodostavat vety ja (C1-Ca)alkyyli.
7. Patenttivaatimuksen 6 mukainen yhdiste, jossa R* on valittu ryhmästä, jonka muodostavat vety ja metyyli.
8. Jonkin patenttivaatimuksista 1, 2, 3, 4, 5, 6 ja 7 mukainen yhdiste, jossa efektori on diagnostisesti aktiivinen radionuklidi tai terapeuttisesti aktiivinen radionuklidi.
9. Jonkin patenttivaatimuksista 1-8 mukainen yhdiste, jossa radionuklidi on valittu ryhmästä, jonka muodostavat '5"In, YMTc, 9Ga, *?Fe, Ga, ”As, In Ru, Pb, Cu Cu Cr SmMn 157Gd Tr 177 u Sc 7Cu 212pp 225A¢ 213B; Oy 18F 1201 1231 1241 1251 1291 1311 75Br 76Br "Br Br ja 211At 186R a 69Er 121gp 127Te 1492p, 143Pr 198 Au 19 Au 161Tb 109Ppg 18SRd 188Re TI As 166Dy 166 Pm I5lPm 155Sm 159Gd 12Tm 169Yh 175Yb 105Rh I Ag 177MSn 227Th 101 113m] 14m], Fe SIMn Co 58Co 75Se S2MRh S3Sr 86y 94m Hg 201m 2p 3p Sc TI As 80mBr 89Qr Mo 103mRh 109pg 109p¢ 119g} Dy 1555m 161 169E 169y1y 12Tm 189Re 189M()5 1921, 1941, 211At 211pp 212pp 211Bi 20Bi 215P, 217 At 219Rn 221Fr 223Ra ja ””Fm.
10. Patenttivaatimuksen 9 mukainen yhdiste, jossa radionuklidi on valittu ryhmästä, jonka muodostavat In, "Lu ja YTc.
11. Patenttivaatimuksen 9 mukainen yhdiste, jossa radionuklidi on "In.
12. — Patenttivaatimuksen 9 mukainen yhdiste, jossa radionuklidi on Lu.
13. — Patenttivaatimuksen 9 mukainen yhdiste, jossa radionuklidi on PfTc.
14. Patenttivaatimuksen 9 mukainen yhdiste, jossa radionuklidi on 22°Ac.
15. — Jonkin patenttivaatimuksista 1-14 mukainen yhdiste, jossa akseptori on kelaattori tai aromaatti, jolloin aromaatti on edullisesti elektronirikas aromaatti.
16. Jonkin patenttivaatimuksista 1-15 mukainen yhdiste, jossa kelaattori on kelaattori valittuna ryhmästä, jonka muodostavat DOTA, NOTA, DTPA, TETA, EDTA, NO- DAGA, NODASA, TRITA, CDTA, BAT, DFO ja HYNIC.
17 Patenttivaatimuksen 16 mukainen yhdiste, jossa kelaattori on DOTA.
18. — Jonkin patenttivaatimuksista 1-15 mukainen yhdiste, jossa akseptori on elektroni- rikas aromaatti.
19. Patenttivaatimuksen 18 mukainen yhdiste, jossa elektronirikas aromaatti on va- littu ryhmästä, jonka muodostavat indoli ja bentseeni, jolloin bentseeni on substituoitu vähintään yhdellä heteroatomilla, jolloin heteroatomi on valittu ryhmästä, joka käsittää O:n, N:n ja S:n.
20. Jonkin patenttivaatimuksista 1-19 mukainen yhdiste käytettäväksi sairauden diagnosoimiseksi.
21. Jonkin patenttivaatimuksista 1-19 mukainen yhdiste käytettäväksi menetelmässä sairauden hoitamiseksi.
22. Jonkin patenttivaatimuksista 1-19 mukainen yhdiste käytettäväksi menetelmässä kohteen tunnistamiseksi, jolloin kohde todennäköisesti reagoi tai todennäköisesti ei rea- goi sairauden hoitoon, jolloin menetelmä kohteen tunnistamiseksi käsittää diagnosointi- menetelmän suorittamisen käyttäen jonkin patenttivaatimuksista 1-19 mukaista yhdis- — tettä, edullisesti patenttivaatimuksessa 20 kuvatun menetelmän sairauden diagnosoi- miseksi.
23. Jonkin patenttivaatimuksista 1-19 mukainen yhdiste käytettäväksi menetelmässä kohteiden ryhmän osittamiseksi kohteisiin, jotka todennäköisesti reagoivat sairauden hoi- toon, ja kohteisiin, jotka todennäköisesti eivät reagoi sairauden hoitoon, jolloin mene- telmä kohteiden ryhmän osittamiseksi käsittää diagnosointimenetelmän suorittamisen 5 — käyttäen jonkin patenttivaatimuksista 1-19 mukaista yhdistettä, edullisesti patenttivaati- muksessa 20 kuvatun menetelmän sairauden diagnosoimiseksi.
24. Yhdiste käytettäväksi jonkin patenttivaatimuksista 20, 21, 22 ja 23 mukaisesti, jolloin sairaus on neurotensiinireseptoriin liittyvä sairaus, edullisesti sairaus on neuroten- — siinireseptori 1:een liittyvä sairaus, ja edullisemin sairaus on valittu ryhmästä, joka käsit- tää kasvaimet ja hematologiset pahanlaatuisuudet.
25. — Koostumus, edullisesti farmaseuttinen koostumus, jossa koostumus käsittää jon- kin patenttivaatimuksista 1-19 mukaisen yhdisteen ja farmaseuttisesti hyväksyttävän — apuaineen.
26. — Kitti, joka käsittää jonkin patenttivaatimuksista 1-19 mukaisen yhdisteen, yhden tai useamman valinnaisen apuaineen ja valinnaisesti yhden tai useamman laitteen, jolloin laite (laitteet) on/ovat valittu ryhmästä, joka käsittää etiketöintilaitteen, puhdistuslaitteen, — käsittelylaitteen, säteilysuojalaitteen, analyyttisen laitteen tai antamislaitteen.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12008208.6A EP2740726A1 (en) | 2012-12-07 | 2012-12-07 | Neurotensin receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3712131T3 true FI3712131T3 (fi) | 2023-03-28 |
Family
ID=47355771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20166422.4T FI3712131T3 (fi) | 2012-12-07 | 2013-12-06 | Neurotensiinireseptoriligandeja |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10961199B2 (fi) |
| EP (3) | EP2740726A1 (fi) |
| JP (2) | JP6576828B2 (fi) |
| KR (1) | KR102290803B1 (fi) |
| CN (2) | CN109320502B (fi) |
| AU (1) | AU2013354422B2 (fi) |
| BR (1) | BR112015012530B1 (fi) |
| CA (1) | CA2893605C (fi) |
| DK (2) | DK3712131T3 (fi) |
| ES (2) | ES2941629T3 (fi) |
| FI (1) | FI3712131T3 (fi) |
| HK (1) | HK1210148A1 (fi) |
| HU (2) | HUE050388T2 (fi) |
| IL (1) | IL239080B (fi) |
| MX (1) | MX370354B (fi) |
| PL (2) | PL2928870T3 (fi) |
| PT (2) | PT2928870T (fi) |
| RU (1) | RU2671970C2 (fi) |
| SG (2) | SG10201704564QA (fi) |
| WO (1) | WO2014086499A1 (fi) |
| ZA (1) | ZA201503446B (fi) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7065567B2 (ja) * | 2014-06-10 | 2022-05-12 | スリービー・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ニューロテンシン受容体リガンドを含むコンジュゲートおよびそれらの使用 |
| EP2954934A1 (en) * | 2014-06-11 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand and use thereof |
| EP2954933A1 (en) * | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand |
| PL3380495T3 (pl) | 2015-11-24 | 2021-12-13 | Transfert Plus, S.E.C. | Związki peptydowe i koniugaty peptydowe do leczenia nowotworu poprzez chemioterapię receptorową |
| EP3279197A1 (en) | 2016-08-03 | 2018-02-07 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnosis, treatment and prevention of neurotensin receptor-related conditions |
| JP7105235B2 (ja) | 2016-12-01 | 2022-07-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔイメージングのための放射性標識された抗ｐｄ－ｌ１抗体 |
| IL268667B1 (en) | 2017-02-10 | 2024-08-01 | Regeneron Pharma | Radiolabeled antibodies against LAG3 for immuno-PET imaging |
| SG11202000073XA (en) | 2017-07-24 | 2020-02-27 | Regeneron Pharma | Anti-cd8 antibodies and uses thereof |
| CN118406106A (zh) * | 2019-07-08 | 2024-07-30 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
| CN111875667B (zh) * | 2020-07-16 | 2021-12-21 | 南方科技大学 | 有机金属螯合物及其制备方法与应用、探针 |
| CA3196365A1 (en) * | 2020-10-22 | 2022-04-28 | Tomoyuki Imai | Method for producing radioactive zirconium complex |
| WO2022241470A1 (en) * | 2021-05-13 | 2022-11-17 | The General Hospital Corporation | Molecular probes for in vivo detection of aldehydes |
| WO2022261770A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and folfirinox |
| WO2022261771A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel |
| WO2023141722A1 (en) * | 2022-01-28 | 2023-08-03 | Fusion Pharmaceuticals Inc. | Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy |
| AU2023221977A1 (en) * | 2022-02-18 | 2024-08-15 | Full-Life Technologies Hk Limited | Compounds and radioligands for targeting neurotensin receptor and uses thereof |
| WO2023215778A1 (en) * | 2022-05-03 | 2023-11-09 | The University Of North Carolina At Chapel Hill | Development of ntsr targeted agents for imaging and therapy applications |
| US12091454B2 (en) | 2022-12-28 | 2024-09-17 | Development Center For Biotechnology | Humanized anti-human neurotensin receptor 1 antibodies and their uses |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110321A (en) | 1976-07-12 | 1978-08-29 | Folkers Karl | Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity |
| US4425269A (en) | 1982-06-07 | 1984-01-10 | Merck & Co., Inc. | Metabolically protected analogs of neurotensin |
| US4439359A (en) | 1982-07-02 | 1984-03-27 | Merck & Co., Inc. | Cyclic octapeptide analogs of neurotensin |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| CA2086453A1 (en) | 1992-12-30 | 1994-07-01 | Mcgill University | Marker for neurotensin receptor |
| US5407916A (en) | 1993-02-16 | 1995-04-18 | Warner-Lambert Company | Neurotensin mimetics as central nervous system agents |
| FR2711140B1 (fr) * | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
| CA2183421A1 (en) | 1994-02-18 | 1995-08-24 | John Mertens | Labelled peptide compounds |
| US6054557A (en) | 1995-04-04 | 2000-04-25 | Advanced Bioconcept (1994) Ltd. | Fluorescent peptides |
| WO1996031531A2 (en) | 1995-04-04 | 1996-10-10 | Advanced Bioconcept, Inc. | Fluorescent peptides |
| FR2732967B1 (fr) * | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
| WO1997004311A2 (en) | 1995-07-20 | 1997-02-06 | Advanced Bioconcept, Inc. | Cell sorting with fluorescent peptides |
| HUP0001316A3 (en) | 1997-02-03 | 2001-10-29 | Mallinckrodt Inc | Method for the detection and localization of malignant human tumours |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| US6214790B1 (en) | 1998-04-10 | 2001-04-10 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| WO2000078796A2 (en) | 1999-06-24 | 2000-12-28 | Mallinckrodt Inc. | Labeled neurotensin derivatives with improved resistance to enzymatic degradation |
| CA2530224A1 (en) * | 2003-07-09 | 2005-02-24 | California Pacific Medical Center | Remote detection of substance delivery to cells |
| US20060062729A1 (en) * | 2004-09-09 | 2006-03-23 | Carraway Robert E | Enhanced ligand binding to neurotensin receptors |
| WO2008091530A2 (en) * | 2007-01-19 | 2008-07-31 | Mallinckrodt Inc. | Diagnostic and therapeutic cyclooxygenase-2 binding ligands |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| JP5592377B2 (ja) * | 2008-09-16 | 2014-09-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 放射能標識のための［１８ｆ］ｓｆｂの単純化ワンポット合成 |
| MX2011005963A (es) | 2008-12-05 | 2011-09-01 | Angiochem Inc | Conjugados de neurotensina o analogos de neurotensina y sus usos. |
| ES2538002T3 (es) * | 2009-01-07 | 2015-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama |
| EP2454272B1 (en) | 2009-07-16 | 2017-08-23 | IASON GmbH | Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors |
| WO2011156557A2 (en) * | 2010-06-11 | 2011-12-15 | Thomas James B | Compounds active at the neurotensin receptor |
-
2012
- 2012-12-07 EP EP12008208.6A patent/EP2740726A1/en not_active Withdrawn
-
2013
- 2013-12-06 ES ES20166422T patent/ES2941629T3/es active Active
- 2013-12-06 RU RU2015127086A patent/RU2671970C2/ru active
- 2013-12-06 HU HUE13814827A patent/HUE050388T2/hu unknown
- 2013-12-06 EP EP20166422.4A patent/EP3712131B1/en active Active
- 2013-12-06 DK DK20166422.4T patent/DK3712131T3/da active
- 2013-12-06 US US14/650,437 patent/US10961199B2/en active Active
- 2013-12-06 EP EP13814827.5A patent/EP2928870B1/en active Active
- 2013-12-06 ES ES13814827T patent/ES2795923T3/es active Active
- 2013-12-06 KR KR1020157018171A patent/KR102290803B1/ko active IP Right Grant
- 2013-12-06 PT PT138148275T patent/PT2928870T/pt unknown
- 2013-12-06 JP JP2015545697A patent/JP6576828B2/ja active Active
- 2013-12-06 AU AU2013354422A patent/AU2013354422B2/en active Active
- 2013-12-06 WO PCT/EP2013/003700 patent/WO2014086499A1/en active Application Filing
- 2013-12-06 CN CN201811305966.0A patent/CN109320502B/zh active Active
- 2013-12-06 PL PL13814827T patent/PL2928870T3/pl unknown
- 2013-12-06 CN CN201380063364.8A patent/CN104837819B9/zh active Active
- 2013-12-06 PL PL20166422.4T patent/PL3712131T3/pl unknown
- 2013-12-06 MX MX2015007193A patent/MX370354B/es active IP Right Grant
- 2013-12-06 SG SG10201704564QA patent/SG10201704564QA/en unknown
- 2013-12-06 FI FIEP20166422.4T patent/FI3712131T3/fi active
- 2013-12-06 SG SG11201503880YA patent/SG11201503880YA/en unknown
- 2013-12-06 CA CA2893605A patent/CA2893605C/en active Active
- 2013-12-06 BR BR112015012530-1A patent/BR112015012530B1/pt active IP Right Grant
- 2013-12-06 DK DK13814827.5T patent/DK2928870T3/da active
- 2013-12-06 PT PT201664224T patent/PT3712131T/pt unknown
- 2013-12-06 HU HUE20166422A patent/HUE061839T2/hu unknown
-
2015
- 2015-05-18 ZA ZA2015/03446A patent/ZA201503446B/en unknown
- 2015-05-28 IL IL239080A patent/IL239080B/en active IP Right Grant
- 2015-11-03 HK HK15110838.8A patent/HK1210148A1/xx unknown
-
2019
- 2019-08-21 JP JP2019150947A patent/JP7042776B2/ja active Active
-
2020
- 2020-12-04 US US17/112,258 patent/US20210087149A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3712131T3 (fi) | Neurotensiinireseptoriligandeja | |
| TWI657827B (zh) | 用於正子斷層掃描之化合物 | |
| JP2019218375A5 (fi) | ||
| JP2004505095A5 (fi) | ||
| BR112019023246B1 (pt) | Compostos compreendendo uma fração quelante, métodos para produção dos mesmos e usos dos mesmos | |
| JP2016521256A5 (fi) | ||
| Dörner et al. | Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood− brain barrier | |
| MX2010005342A (es) | Compuestos indola y metodos para tratar el dolor visceral. | |
| WO2010065950A3 (en) | Albumin binding peptide-mediated disease targeting | |
| CA2643744A1 (en) | Cancer imaging and treatment | |
| JP2019525891A5 (fi) | ||
| HRP20240398T1 (hr) | Označeni inhibitori prostata specifičnog membranskog antigena (psma), njihova upotreba kao sredstava za snimanje i farmaceutska sredstva za liječenje raka prostate | |
| NZ602824A (en) | Sparc binding peptides and uses thereof | |
| JP2017503011A5 (fi) | ||
| WO2007088489A3 (en) | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same | |
| KR20210148157A (ko) | Hsp90-결합 접합체 및 이의 제형 | |
| WO2007095443A3 (en) | Gastrin releasing peptide compounds | |
| IN2014DN05869A (fi) | ||
| TWI605815B (zh) | 用於製備包含阿米福丁與胺基酸之腎保護劑的組成物及方法 | |
| CN112074288A (zh) | Hsp90-靶向缀合物及其制剂 | |
| JP2011506436A5 (fi) | ||
| JP2024123022A (ja) | ガストリン放出ペプチド受容体（ｇｒｐｒ）のインビボイメージングおよびｇｒｐｒ関連障害の治療のための放射性標識ボンベシン由来化合物 | |
| JP2004524323A5 (fi) | ||
| TW202131946A (zh) | 持續性免疫療法 | |
| US11406723B2 (en) | Radiotherapeutic and companion imaging agents to target MC1R |